Industry Growth Insights published a new data on “Targeted Drugs for Multiple Myeloma Market”. The research report is titled “Targeted Drugs for Multiple Myeloma Market research by Types (Immunomodulator, Proteasome Inhibitors, Histone Deacetylase Inhibitors (HDACI), Monoclonal Antibody, Other), By Applications (Hospital, Drug Center, Clinic, Other), By Players/Companies Celgene, Exova, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories, Qilu Pharmaceutical, Chia Tai-Tianqing, Hanson Pharm, Meidakang Huakang Pharmaceutical, Shandong Kongfu Pharmaceutical, J&J, Takeda, Amgen, Bristol Myers Squibb, Abbvie, Seattle Genetics, Karyopharm Therapeutics, PDL BioPharma, Roche, Sumitomo, Merck, Biogen, Schering-Plough, Glaxo, Chiron”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Targeted Drugs for Multiple Myeloma Market Research Report
By Type
Immunomodulator, Proteasome Inhibitors, Histone Deacetylase Inhibitors (HDACI), Monoclonal Antibody, Other
By Application
Hospital, Drug Center, Clinic, Other
By Companies
Celgene, Exova, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories, Qilu Pharmaceutical, Chia Tai-Tianqing, Hanson Pharm, Meidakang Huakang Pharmaceutical, Shandong Kongfu Pharmaceutical, J&J, Takeda, Amgen, Bristol Myers Squibb, Abbvie, Seattle Genetics, Karyopharm Therapeutics, PDL BioPharma, Roche, Sumitomo, Merck, Biogen, Schering-Plough, Glaxo, Chiron
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
202
Number of Tables & Figures
142
Customization Available
Yes, the report can be customized as per your need.
Global Targeted Drugs for Multiple Myeloma Market Report Segments:
The global Targeted Drugs for Multiple Myeloma market is segmented on the basis of:
Types
Immunomodulator, Proteasome Inhibitors, Histone Deacetylase Inhibitors (HDACI), Monoclonal Antibody, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drug Center, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene
- Exova
- Natco Pharma
- Intas Pharmaceuticals
- Indiabulls Pharmaceutical
- Cipla
- Glenmark Pharmaceuticals
- Dr Reddy's Laboratories
- Qilu Pharmaceutical
- Chia Tai-Tianqing
- Hanson Pharm
- Meidakang Huakang Pharmaceutical
- Shandong Kongfu Pharmaceutical
- J&J
- Takeda
- Amgen
- Bristol Myers Squibb
- Abbvie
- Seattle Genetics
- Karyopharm Therapeutics
- PDL BioPharma
- Roche
- Sumitomo
- Merck
- Biogen
- Schering-Plough
- Glaxo
- Chiron
Highlights of The Targeted Drugs for Multiple Myeloma Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immunomodulator
- Proteasome Inhibitors
- Histone Deacetylase Inhibitors (HDACI)
- Monoclonal Antibody
- Other
- By Application:
- Hospital
- Drug Center
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Targeted Drugs for Multiple Myeloma Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Targeted drugs for multiple myeloma are medications that specifically target the cancerous cells in the body. These drugs can help to slow or stop the growth of the cancer, and may also help to improve symptoms. Some targeted drugs are approved by the U.S. Food and Drug Administration (FDA) as first-line treatments for multiple myeloma, while others are investigational or experimental therapies.
Some of the major players in the targeted drugs for multiple myeloma market are Celgene, Exova, Natco Pharma, Intas Pharmaceuticals, Indiabulls Pharmaceutical, Cipla, Glenmark Pharmaceuticals, Dr Reddy's Laboratories, Qilu Pharmaceutical, Chia Tai-Tianqing, Hanson Pharm, Meidakang Huakang Pharmaceutical, Shandong Kongfu Pharmaceutical, J&J, Takeda, Amgen, Bristol Myers Squibb, Abbvie, Seattle Genetics, Karyopharm Therapeutics, PDL BioPharma, Roche, Sumitomo, Merck, Biogen, Schering-Plough, Glaxo, Chiron.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Targeted Drugs for Multiple Myeloma Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Targeted Drugs for Multiple Myeloma Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Targeted Drugs for Multiple Myeloma Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Targeted Drugs for Multiple Myeloma Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Targeted Drugs for Multiple Myeloma Market Size & Forecast, 2018-2028
4.5.1 Targeted Drugs for Multiple Myeloma Market Size and Y-o-Y Growth
4.5.2 Targeted Drugs for Multiple Myeloma Market Absolute $ Opportunity
Chapter 5 Global Targeted Drugs for Multiple Myeloma Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Targeted Drugs for Multiple Myeloma Market Size Forecast by Type
5.2.1 Immunomodulator
5.2.2 Proteasome Inhibitors
5.2.3 Histone Deacetylase Inhibitors (HDACI)
5.2.4 Monoclonal Antibody
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Targeted Drugs for Multiple Myeloma Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Targeted Drugs for Multiple Myeloma Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drug Center
6.2.3 Clinic
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Targeted Drugs for Multiple Myeloma Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Targeted Drugs for Multiple Myeloma Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Targeted Drugs for Multiple Myeloma Analysis and Forecast
9.1 Introduction
9.2 North America Targeted Drugs for Multiple Myeloma Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Targeted Drugs for Multiple Myeloma Market Size Forecast by Type
9.6.1 Immunomodulator
9.6.2 Proteasome Inhibitors
9.6.3 Histone Deacetylase Inhibitors (HDACI)
9.6.4 Monoclonal Antibody
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Targeted Drugs for Multiple Myeloma Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drug Center
9.10.3 Clinic
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Targeted Drugs for Multiple Myeloma Analysis and Forecast
10.1 Introduction
10.2 Europe Targeted Drugs for Multiple Myeloma Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Targeted Drugs for Multiple Myeloma Market Size Forecast by Type
10.6.1 Immunomodulator
10.6.2 Proteasome Inhibitors
10.6.3 Histone Deacetylase Inhibitors (HDACI)
10.6.4 Monoclonal Antibody
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Targeted Drugs for Multiple Myeloma Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drug Center
10.10.3 Clinic
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Targeted Drugs for Multiple Myeloma Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Targeted Drugs for Multiple Myeloma Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Targeted Drugs for Multiple Myeloma Market Size Forecast by Type
11.6.1 Immunomodulator
11.6.2 Proteasome Inhibitors
11.6.3 Histone Deacetylase Inhibitors (HDACI)
11.6.4 Monoclonal Antibody
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Targeted Drugs for Multiple Myeloma Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drug Center
11.10.3 Clinic
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Targeted Drugs for Multiple Myeloma Analysis and Forecast
12.1 Introduction
12.2 Latin America Targeted Drugs for Multiple Myeloma Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Targeted Drugs for Multiple Myeloma Market Size Forecast by Type
12.6.1 Immunomodulator
12.6.2 Proteasome Inhibitors
12.6.3 Histone Deacetylase Inhibitors (HDACI)
12.6.4 Monoclonal Antibody
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Targeted Drugs for Multiple Myeloma Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drug Center
12.10.3 Clinic
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Targeted Drugs for Multiple Myeloma Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Targeted Drugs for Multiple Myeloma Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Targeted Drugs for Multiple Myeloma Market Size Forecast by Type
13.6.1 Immunomodulator
13.6.2 Proteasome Inhibitors
13.6.3 Histone Deacetylase Inhibitors (HDACI)
13.6.4 Monoclonal Antibody
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Targeted Drugs for Multiple Myeloma Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drug Center
13.10.3 Clinic
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Targeted Drugs for Multiple Myeloma Market: Competitive Dashboard
14.2 Global Targeted Drugs for Multiple Myeloma Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Celgene
14.3.2 Exova
14.3.3 Natco Pharma
14.3.4 Intas Pharmaceuticals
14.3.5 Indiabulls Pharmaceutical
14.3.6 Cipla
14.3.7 Glenmark Pharmaceuticals
14.3.8 Dr Reddy's Laboratories
14.3.9 Qilu Pharmaceutical
14.3.10 Chia Tai-Tianqing
14.3.11 Hanson Pharm
14.3.12 Meidakang Huakang Pharmaceutical
14.3.13 Shandong Kongfu Pharmaceutical
14.3.14 J&J
14.3.15 Takeda
14.3.16 Amgen
14.3.17 Bristol Myers Squibb
14.3.18 Abbvie
14.3.19 Seattle Genetics
14.3.20 Karyopharm Therapeutics
14.3.21 PDL BioPharma
14.3.22 Roche
14.3.23 Sumitomo
14.3.24 Merck
14.3.25 Biogen
14.3.26 Schering-Plough
14.3.27 Glaxo
14.3.28 Chiron
